Objective: The mortality and morbidity rates associated with pancreatic cancer (PaCa) are extremely high. Various studies have demonstrated that pancreatic cancer will be the fourth cancer-related death by 2030, raising more concern for scholars to find effective methods to prevent and treat in order to improve the pancreatic cancer outcome. Using bioinformatic analysis, this study aims to pinpoint key genes that could impact PaCa patients’ prognosis and could be used as therapeutic targets. Methods: The TCGA and GEO datasets were integratively analyzed to identify prognosis-related differentially expressed genes. Next, the STRING database was used to develop PPI networks, and the MCODE and CytoNCA Cytoscape in Cytoscape were used to screen for critical genes. Through CytoNCA, three kinds of topology analysis were considered (degree, betweenness, and eigenvector). Essential genes were confirmed as potential target treatment through Go function and pathways enrichment analysis, a developed predictive risk model based on multivariate analysis, and the establishment of nomograms using the clinical information. Results: Overall, the GSE183795 and TCGA datasets associated 1311 and 2244 genes with pancreatic cancer prognosis, respectively. We identified 132 genes that were present in both datasets. The PPI network analysis using, the centrality analysis approach with the CytoNCA plug-in, showed that CDK2, PLK1, CCNB1, and TOP2A ranked in the top 5% across all three metrics. The independent analysis of a risk model revealed that the four key genes had a Hazard Ratio (HR) > 1. The monogram showed the predictive risk model and individual patient survival predictions were accurate. The results indicate that the effect of the selected vital genes was significant and that they could be used as biomarkers to predict a patient’s outcome and as possible target therapy in patients with pancreatic cancer. GO function and pathway analysis demonstrated that crucial genes might affect the P53 signaling pathway and FoxO signaling pathway, through which Meiotic nuclear division and cell cycle may have a significant function in essential genes affecting the outcome of patients who have pancreatic cancer. Conclusions: This study suggests that CDK2, CCNB1, PLK1 and TOP2A are four key genes that have a significant influence on PaCa migration and proliferation. CDK2, CCNB1, PLK1, and TOP2A can be used as potential PaCa prognostic biomarkers and therapeutic targets. However, experimental validation is necessary to confirm these predictions.
References
[1]
Siegel, R.L., Miller, K.D., Fuchs, H.E. and Jemal, A. (2021) Cancer Statistics, 2021. CA: A Cancer Journal for Clinicians, 71, 7-33. https://doi.org/10.3322/caac.21654
[2]
Kleeff, J., Korc, M., Apte, M., La Vecchia, C., Johnson, C.D., Biankin, A.V., Neale, R.E., Tempero, M., Tuveson, D.A., Hruban, R.H. and Neoptolemos, J.P. (2016) Pancreatic Cancer. Nature Reviews Disease Primers, 2, Article No. 16022. https://doi.org/10.1038/nrdp.2016.22
[3]
Jones, S., Zhang, X., Parsons, D.W., Lin, J.C., Leary, R.J., Angenendt, P., et al. (2008) Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses. Science, 321, 1801-1806. https://doi.org/10.1126/science.1164368
[4]
Gnoni, A., Licchetta, A., Scarpa, A., Azzariti, A., Brunetti, A.E., Simone, G., Nardulli, P., Santini, D., Aieta, M., Delcuratolo, S. and Silvestris, N. (2013) Carcinogenesis of Pancreatic Adenocarcinoma: Precursor Lesions. International Journal of Molecular Sciences, 14, 19731-19762. https://doi.org/10.3390/ijms141019731
[5]
Goujon, M., McWilliam, H., Li, W., Valentin, F., Squizzato, S., Paern, J. and Lopez, R. (2010) A New Bioinformatics Analysis Tools Framework at EMBL-EBI. Nucleic Acids Research, 38, W695-W699. https://doi.org/10.1093/nar/gkq313
[6]
Zhang, W., Li, F. and Nie, L. (2010) Integrating Multiple ‘Omics’ Analysis for Microbial Biology: Application and Methodologies. Microbiology (Reading), 156, 287-301.
[7]
The Cancer Genome Atlas Research Network (2017) Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma. CancerCell, 32, 185-203.e13. https://doi.org/10.1016/j.ccell.2017.07.007
[8]
Rahib, L., Smith, B.D., Aizenberg, R., Rosenzweig, A.B., Fleshman, J.M. and Matrisian, L.M. (2014) Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States. Cancer Research, 74, 2913-2921. https://doi.org/10.1158/0008-5472.CAN-14-0155
[9]
Rawat, M., Kadian, K., Gupta, Y., Kumar, A., Chain, P.S.G., Kovbasnjuk, O., Kumar, S. and Parasher, G. (2019) MicroRNA in Pancreatic Cancer: From Biology to Therapeutic Potential. Genes, 10, Article 752. https://doi.org/10.3390/genes10100752
[10]
Tang, Y., Li, M., Wang, J., Pan, Y. and Wu, F.X. (2015) CytoNCA: A Cytoscape Plugin for Centrality Analysis and Evaluation of Protein Interaction Networks. Biosystems, 127, 67-72. https://doi.org/10.1016/j.biosystems.2014.11.005
[11]
Langfelder, P. and Horvath, S. (2008) WGCNA: An R Package for Weighted Correlation Network Analysis. BMC Bioinformatics, 9, Article No. 559.
[12]
Lu, Y., Li, A., Lai, X., Jiang, J., Zhang, L., Zhong, Z., et al. (2019) Identification of Differentially Expressed Genes and Signaling Pathways Using Bioinformatics in Interstitial Lung Disease Due to Tyrosine Kinase Inhibitors Targeting the Epidermal Growth Factor Receptor. Investigational New Drugs, 37, 384-400. https://doi.org/10.1007/s10637-018-0664-z
[13]
Pines, J. (2006) Mitosis: A Matter of Getting Rid of the Right Protein at the Right Time. Trends in Cell Biology, 16, 55-63. https://doi.org/10.1016/j.tcb.2005.11.006
[14]
Kawamoto, H., Koizumi, H., Uchikoshi, T. (1997) Expression of the G2-m Checkpoint Regulators Cyclin Bl and cdc2 in Nonmalignant and Malignant Human Breast Lesions: Immunovtochemical and Quantitative Image Analyses. The American Journal of Pathology, 150, 15-23.
[15]
Soria, J.C., Jang, S.J., Khuri, F.R., Hassan, K., Liu, D., Hong, W.K., et al. (2000) Overexpression of Cyclin B1 in Early-Stage Non-Small Cell Lung Cancer and Its Clinical Implication. Cancer Research, 60, 4000-4004.
[16]
Hassan, K.A., Ang, K.K., El-Naggar, A.K., Story, M.D., Lee, J.I., Liu, D., et al. (2002) Cyclin B1 Overexpression and Resistance to Radiotherapy in Head and Neck Squamous Cell Carcinoma. Cancer Research, 62, 6414-6417.
[17]
Kallakury, M.D., Sheehan, B.S., Rhee, M.D., Fisher, M.D., Kaufman, Jr., Rifkin, M.D., et al. (1999) The Prognostic Significance of Proliferation-Associated Nucleolar Protein p120 Expression in Prostate Adenocarcinoma: A Comparison with Cyclins A and B1, Ki-67, Proliferating Cell Nuclear Antigen, and p34cdc2. Cancer, 85, 1569-1576. https://doi.org/10.1002/(SICI)1097-0142(19990401)85:7%3C1569::AID-CNCR19%3E3.0.CO;2-M
[18]
LaTulippe, E., Satagopan, J., Smith, A., Scher, H., Scardino, P., Reuter, V., et al. (2002) Comprehensive Gene Expression Analysis of Prostate Cancer Reveals Distinct Transcriptional Programs Associated with Metastatic Disease. Cancer Research, 62, 4499-4506.
[19]
Glinsky, G.V., Berezovska, O. and Glinskii, A.B. (2005) Microarray Analysis Identifies a Death-from-Cancer Signature Predicting Therapy Failure in Patients with Multiple Types of Cancer. Journal of Clinical Investigation, 115, 1503-1521. https://doi.org/10.1172/JCI23412
[20]
Xie, B., Wang, S., Jiang, N. and Li, J.J. (2019) Cyclin B1/CDK1-Regulated Mitochondrial Bioenergetics in Cell Cycle Progression and Tumor Resistance. Cancer Letters, 443, 56-66. https://doi.org/10.1016/j.canlet.2018.11.019
[21]
Ramani, P., et al. (2015) High Levels of Polo-Like Kinase 1 and Phosphorylated Translationally Controlled Tumor Protein Indicate Poor Prognosis in Neuroblastomas. Journal of Neuro-Oncology, 125, 103-111. https://doi.org/10.1007/s11060-015-1900-4
[22]
Tut, T.G., et al. (2015) Upregulated Polo-Like Kinase 1 Expression Correlates with Inferior Survival Outcomes in Rectal Cancer. PLOS ONE, 10, e0129313.
[23]
Zhang, R., et al. (2015) Misregulation of Polo-Like Protein Kinase 1, P53 and P21WAF1 in Epithelial Ovarian Cancer Suggests Poor Prognosis. Oncology Reports, 33, 1235-1242. https://doi.org/10.3892/or.2015.3723
[24]
Lens, S.M., Voest, E.E. and Medema, R.H. (2010) Shared and Separate Functions of Polo-Like Kinases and Aurora Kinases in Cancer. Nature Reviews Cancer, 10, 825-841. https://doi.org/10.1038/nrc2964
[25]
de Oliveira, J.C., et al. (2012) In vitro PLK1 Inhibition by BI 2536 Decreases Proliferation and Induces Cell-Cycle Arrest in Melanoma Cells. Journal of Drugs in Dermatology, 11, 587-592.
[26]
Bu, Y., et al. (2008) Silencing of Polo-Like Kinase (Plk) 1 via siRNA Causes Inhibition of Growth and Induction of Apoptosis in Human Esophageal Cancer Cells. Oncology, 74, 198-206. https://doi.org/10.1159/000151367
[27]
Liu, Q., Gao, J., Zhao, C., Guo, Y., Wang, S., Shen, F., Xing, X. and Luo, Y. (2020) To Control or to Be Controlled? Dual Roles of CDK2 in DNA Damage and DNA Damage Response. DNA Repair, 85, Article 102702. https://doi.org/10.1016/j.dnarep.2019.102702
[28]
Chohan, T.A., Qian, H., Pan, Y. and Chen, J.Z. (2015) Cyclin-Dependent Kinase-2 as a Target for Cancer Therapy: Progress in the Development of CDK2 Inhibitors as Anti-Cancer Agents. Current Medicinal Chemistry, 22, 237-263. https://doi.org/10.2174/0929867321666141106113633
[29]
Maddison, L.A., Huss, W.J., Barrios, R.M. and Greenberg, N.M. (2004) Differential Expression of Cell Cycle Regulatory Molecules and Evidence for a “Cyclin Switch” during Progression of Prostate Cancer. Prostate, 58, 335-344. https://doi.org/10.1002/pros.10341
[30]
Keyomarsi, K., O’Leary, N., Molnar, G., Lees, E., Fingert, H.J. and Pardee, A.B. (1994) Cyclin E, a Potential Prognostic Marker for Breast Cancer. Cancer Research, 54, 380-385.
[31]
Yang, R.M., Naitoh, J., Murphy, M., Wang, H.J., Phillipson, J., deKernion, J.B., Loda, M. and Reiter, R.E. (1998) Low p27 Expression Predicts Poor Disease-Free Survival in Patients with Prostate Cancer. The Journal of Urology, 159, 941-945. https://doi.org/10.1016/S0022-5347(01)63776-5
[32]
Thomas, G.V., Schrage, M.I., Rosenfelt, L., Kim, J.H., Salur, G., deKernion, J.B., Dorey, F., Said, J. and Reiter, R.E. (2000) Preoperative Prostate Needle Biopsy p27 Correlates with Subsequent Radical Prostatectomy p27, Gleason Grade and Pathological Stage. The Journal of Urology, 164, 1987-1991. https://doi.org/10.1016/S0022-5347(05)66934-0
[33]
Lan, J., Huang, H.Y., Lee, S.W., Chen, T.J., Tai, H.C., Hsu, H.P., Chang, K.Y. and Li, C.F. (2014) TOP2A Overexpression as a Poor Prognostic Factor in Patients with Nasopharyngeal Carcinoma. Tumor Biology. 35, 179-187. https://doi.org/10.1007/s13277-013-1022-6
[34]
Kang, H.A., Shin, H.C., Kalantzi, A.S., Toseland, C.P., Kim, H.M., Gruber, S., et al. (2015) Crystal Structure of Hop2-Mndi and Mechanistic Insights into Its Role in Meiotic Recombination. Nucleic Acids Research, 43, 3841-3856. https://doi.org/10.1093/nar/gkv172
[35]
McFarlane, R.J. and Wakeman, J.A. (2017) Meiosis-Like Functions in Oncogenesis: A New View of Cancer. Cancer Research, 77, 5712-5716. https://doi.org/10.1158/0008-5472.CAN-17-1535
[36]
Whitehurst, A.W. (2014) Cause and Consequence of Cancer/Testis Antigen Activation in Cancer. Annual Review of Pharmacology and Toxicology, 54, 251-272. https://doi.org/10.1146/annurev-pharmtox-011112-140326
[37]
Fratta, E., Coral, S., Covre, A., Parisi, G., Colizzi, F., Danielli, R., et al. (2011) The Biology of Cancer Testis Antigens: Putative Function, Regulation and Therapeutic Potential. Molecular Oncology, 5, 164-182. https://doi.org/10.1016/j.molonc.2011.02.001
[38]
Simpson, A.J.G., Caballero, O.L., Jungbluth, A., Chen, Y.-T. and Old, L.J. (2005) Cancer/Testis Antigens, Gametogenesis and Cancer. Nature Reviews Cancer, 5, 615-625. https://doi.org/10.1038/nrc1669
[39]
Arnoult, N. and Karlseder, J. (2014) ALT Telomeres Borrow from Meiosis to Get Moving. Cell, 159, 11-12. https://doi.org/10.1016/j.cell.2014.09.013
[40]
Cho, N.W., Dilley, R.L., Lampson, M.A. and Greenberg, R.A. (2014) Interchromo-Somal Homology Searches Drive Directional ALT Telomere Movement and Synapsis. Cell, 159, 108-121. https://doi.org/10.1016/j.cell.2014.08.030
[41]
Venkatesan, S., Birkbak, N.J. and Swanton, C. (2017) Constraints in Cancer Evolution. Biochemical Society Transactions, 45, 1-13. https://doi.org/10.1042/BST20160229
[42]
McGranahan, N. and Swanton, C. (2017) Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future. Cell, 168, 613-628. https://doi.org/10.1016/j.cell.2017.01.018
[43]
Vogelstein, B., Lane, D. and Levine, A.J. (2000) Surfing the p53 Network. Nature, 408, 307-310. https://doi.org/10.1038/35042675
[44]
Kastenhuber, E.R. and Lowe, S.W. (2017) Putting p53 in Context. Cell, 170, 1062-1078. https://doi.org/10.1016/j.cell.2017.08.028
[45]
Liu, J., Zhang, C., Hu, W. and Feng, Z. (2019) Tumor Suppressor p53 and Metabolism. Journal of Molecular Cell Biology, 11, 284-292. https://doi.org/10.1093/jmcb/mjy070
[46]
Farhan, M., Wang, H., Gaur, U., Little, P.J., Xu, J. and Zheng, W. (2017) FOXO Signaling Pathways as Therapeutic Targets in Cancer. International Journal of Biological Sciences, 13, 815-827. https://doi.org/10.7150/ijbs.20052
[47]
Matsuzaki, H., Daitoku, H., Hatta, M., et al. (2003) A Insulin-Induced Phosphorylation of FKHR (Foxo1) Targets to Proteasomal Degradation. Proceedings of the National Academy of Sciences of the United States of America, 100, 11285-11290. https://doi.org/10.1073/pnas.1934283100
[48]
Hou, Y.Q., Yao, Y., Bao, Y.L., Song, Z.B., Yang, C., Gao, X.L., Zhang, W.J., Sun, L.G., Yu, C.L., Huang, Y.X., et al. (2016) Juglanthraquinone C Induces Intracellular ROS Increase and Apoptosis by Activating the Akt/Foxo Signal Pathway in HCC Cells. Oxidative Medicine and Cellular Longevity, 2016, Article ID: 4941623. https://doi.org/10.1155/2016/4941623
[49]
Wang, Q., Yu, W.N., Chen, X., Peng, X.D., Jeon, S.M., Birnbaum, M.J., Guzman, G. and Hay, N. (2016) Spontaneous Hepatocellular Carcinoma after the Combined Deletion of Akt Isoforms. Cancer Cell, 29, 523-535. https://doi.org/10.1016/j.ccell.2016.02.008
